EP300 and cancer: The observed higher abundance of the enzyme in nuclei of cisplatin-resistant phenotypes may further suggest that EP300 supports the loss of cancer cell vulnerability to chemotherapeutics by controlling the transcription of numerous genes other than ABCC10, which allows cells to overcome anticancer drug toxicity or influx.